Disease Detail

ID DOID:4007
Name bladder carcinoma
Definition A urinary bladder cancer that has_material_basis_in abnormally proliferating cells derives_from epithelial cells.
Source DiseaseOntology.org
Alt Ids
Path disease disease of cellular proliferation cancer organ system cancer urinary system cancer urinary bladder cancer bladder carcinoma

Filtering

  • Case insensitive filtering will display rows where any text in any cell matches the filter term
  • Simple literal full or partial string matches
  • Separate multiple filter terms with a spaces, order doesn't matter (a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page, filtering has no impact on query parameters
  • Use quotes to match a longer phrase which contains spaces "mtor c1483f"

Sorting

  • Generally, the default sort order for tables is set to be first column ascending, however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column, be sure to set ascending or descending order for a given column, before moving on to the next column.

Molecular Profile Therapy Indication/Tumor Type Response Type Profile Response Detail
FGFR3 wild-type R3Mab bladder carcinoma sensitive detail...
FGFR3 S249C R3Mab bladder carcinoma sensitive detail...
AKT1 E17K NRAS Q61R BAY1125976 bladder carcinoma sensitive detail...
Unknown unknown AR-42 + Cisplatin bladder carcinoma not applicable detail...
HRAS Q61L NS1 bladder carcinoma sensitive detail...
MET wild-type Glesatinib bladder carcinoma decreased response detail...
Clinical Trial Phase Therapies Title Recruitment Status
NCT00942331 Phase III Bevacizumab + Cisplatin + Gemcitabine Cisplatin + Gemcitabine Gemcitabine Hydrochloride and Cisplatin With or Without Bevacizumab in Treating Patients With Advanced Urinary Tract Cancer Active, not recruiting
NCT01259063 Phase Ib/II Everolimus + Gemcitabine RAD001 and Intravesical Gemcitabine in BCG-Refractory Primary or Secondary Carcinoma In Situ of the Bladder Completed
NCT01366144 Phase I Paclitaxel Veliparib Carboplatin Veliparib, Paclitaxel, and Carboplatin in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery and Liver or Kidney Dysfunction Active, not recruiting
NCT01391143 Phase I MGA271 Safety Study of MGA271 in Refractory Cancer Active, not recruiting
NCT01438112 Gemcitabine + interferon gamma + Mitomycin C + Valrubicin CG0070 Efficacy Study of Recombinant Adenovirus for Non Muscle Invasive Bladder Cancer Terminated
NCT01688999 Phase II Cabozantinib Cabozantinib for Advanced Urothelial Cancer Active, not recruiting
NCT01938573 Phase Ib/II Cisplatin + Gemcitabine + Sirolimus Sirolimus, Cisplatin, and Gemcitabine Hydrochloride in Treating Patients With Bladder Cancer Completed
NCT02169284 Phase II Erlotinib Erlotinib Hydrochloride in Treating Patients With Bladder Cancer Undergoing Surgery Terminated
NCT02432963 Phase I MVAp53 + Pembrolizumab Vaccine Therapy and Pembrolizumab in Treating Patients With Solid Tumors That Have Failed Prior Therapy Active, not recruiting
NCT02444793 Phase I Mogamulizumab + Utomilumab A Study of PF-05082566 In Combination With Mogamulizumab In Patients With Advanced Solid Tumors Terminated
NCT02636036 Phase I Enadenotucirev + Pembrolizumab Study of Enadenotucirev and Pembrolizumab in Subjects With Metastatic or Advanced Epithelial Tumors Recruiting
NCT02723955 Phase I GSK3359609 GSK3359609 + Pembrolizumab Dose Escalation and Expansion Study of GSK3359609 in Subjects With Selected Advanced Solid Tumors (INDUCE-1) Recruiting
NCT03171025 Phase II Nivolumab Adjuvant Nivolumab Following Chemo-Radiation in Localized Muscle-Invasive Bladder Cancer (NEXT) Recruiting
NCT03319745 Phase II Pembrolizumab A Window of Opportunity Study of Pembrolizumab in Patients With Bladder Cancer Undergoing Radical Cystectomy Recruiting
NCT03430895 Phase II Durvalumab + Tremelimumab Evaluating Immune Therapy, Durvalumab (MEDI4736) With Tremelimumab for Metastatic, Non-transitional Cell Carcinoma of the Urinary Tract Recruiting
NCT03693014 Phase II A Study of Several Radiation Doses for Patients With Progression on Immunotherapy/Checkpoint Inhibitors Recruiting